Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;52(8):777-787.
doi: 10.1016/j.arcmed.2021.05.007. Epub 2021 Jun 5.

Vasoactive Peptides: Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets

Affiliations
Review

Vasoactive Peptides: Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets

Pariya Khodabakhsh et al. Arch Med Res. 2021 Nov.

Abstract

Background: The ongoing outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as the latest threat to global health, causes overwhelming effects for the public healthcare systems worldwide. Of note, in addition to the respiratory complications, some patients with coronavirus disease 2019 (COVID-19) also develop serious cardiovascular injuries. Vasoactive peptides play an important role in a wide range of physiological and pathological conditions.

Aim: With the urgent need for exploring the specific therapeutic targets and biomarkers for the emerging COVID-19, the general aim of this review is to discuss the potentials of the vasoactive peptides including Angiotensin II (Ang II), vasoactive intestinal peptide (VIP), endothelin-1 (ET-1), calcitonin gene-related peptide (CGRP), natriuretic peptides, substance P (SP) and bradykinin (BK) as therapeutic targets and/or prognostic indicators for the COVID-19 pandemic.

Conclusion: Based on various observations some authors conclude that the assessment of vasoactive peptides shall be considered a routine part of COVID-19 patient monitoring, and they can serve as potential therapeutic targets for the disease management.

Keywords: Angiotensin II; COVID-19; SARS-CoV-2; Vasoactive peptides.

PubMed Disclaimer

Figures

Image, graphical abstract
Graphical abstract
Figure 1
Figure 1
The renin-angiotensin system and action mechanisms of their inhibitor. ACE, angiotensin-converting enzyme; ACEi, ACE inhibitor; ARBs, angiotensin receptor blockers.
Figure 2
Figure 2
The kallikrein-kinin system (KKS) and proposed effects of SARS-CoV-2 on related pathways. BK, bradykinin; Lys-BK, Lys-bradykinin; DABK, des-Arg BK; Lys-DABK, Lys-des-Arg BK; HMWK, high molecular weight kininogen; LMWK, low‐molecular‐weight kininogen; CPM, carboxypeptidase M; CPN, carboxypeptidase N; ACE, angiotensin-converting enzyme.

Similar articles

Cited by

References

    1. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523. - PMC - PubMed
    1. Eurosurveillance Editorial Team Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Euro Surveill. 2020;25 - PMC - PubMed
    1. Available from: https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1?%20. (Accessed March 28, 2021).
    1. Gorbalenya AE, Baker SC, Baric R, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536. - PMC - PubMed
    1. Singhal T. A review of coronavirus disease-2019 (COVID-19) Indian J Pediatr. 2020;87:281–286. doi: 10.1007/s12098-020-03263-6. - DOI - PMC - PubMed